Financial insights of MDCX

MyFinsight

For the quarter ending 2026-03-31.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
General and administrative expenses	5,892,684	28,838,537.75*	-	4,576,524
Research and development expense	2,704,393	3,402,744*	-	1,439,564
Research and development expense (excluding acquired in process cost)	-	2,179,368.75*	-	-
Operating expenses	8,597,077	34,420,650.5	-	6,016,088
Loss from operations	-8,597,077	-34,420,650.5*	-	-6,016,088
Finance (income) expense, net	56,561	-	-	-
Finance income	-	-545,284.5*	-	40,004
Interest (expense)	374,712	-	-	-
Represents the amount of gain loss on settlements	-127,083	-69,713.5*	-	-
Represents the amount if change in fair value of debentures	-	16,177*	-	-200,000
Repayment of debentures on extinguishment	-	-6,250*	-	-
Total other income	-445,234	-605,071*	-	-159,996
Net loss for the year	-9,042,311	-35,025,721.5*	-	-6,176,084
Deemed dividend on warrant inducement	-	2,959,324.5*	-	-
Net income (loss) available to common stockholders, basic	-9,042,311	-37,985,046*	-	-
Foreign exchange gain/loss	-204,249	-43,214*	10,828	-
Comprehensive income (loss), net of tax, attributable to parent	-9,246,560	-38,028,260	-2	-

Basic EPS	-0.31	-2.008	-1.12	-0.43
Diluted EPS	-0.31	-2.008	-1.12	-0.43
Basic Average Shares	29,540,833	18,935,543	18,631,668	14,284,261
Diluted Average Shares	29,540,833	18,935,543	18,631,668	14,284,261